Introduction
Hematopoietic stem cells (HSCs ) exhibit self-renewing capacity as well as the ability to give rise to more committed progenitors which differentiate into all hematopoietic lineages 1 in murine bone marrow progenitors can lead to increased HSC-self-renewal 3 or to the immortalization of stem cell like progenitors capable of undergoing lymphoid and myeloid differentiation both in vitro and in vivo 4 . In addition coculture of murine or human HSCs with immobilized Notch ligands, or feeder cells expressing such ligands, can maintain or even enhance HSC self-renewal [5] [6] [7] [8] [9] .
Recently osteoblasts expressing the Notch ligand Jagged1 (J1) were identified as being part of the hematopoietic stem cell niche. Osteoblast-specific expression of the activated parathyroid hormone-related protein receptor results in increased numbers of osteoblasts expressing high levels of J1. The increase in osteoblasts correlates with an increase in the number of HSCs with evidence of N1 activation in vivo 10 . These results were interpreted to mean that J1-expressing osteoblasts regulate HSC homeostasis through N1 activation.
To definitively assess the role of J1 in the hematopoietic system, we have generated inducible gene targeted mice for J1. Surprisingly, inactivation of J1 in either BM progenitors or BM stromal cells had no effect on HSC maintenance. In addition, N1- 
Study design

Generation and conditional inactivation of mice with a loxP-flanked J1
A J1 genomic clone was isolated from a mouse genomic library using an oligonucleotide complementary to part of the first coding exon. LoxP sites were introduced into an XhoI site and into an AvrII site 1075 bp upstream and 2364 bp downstream of the ATG, flanking the first two coding exons. Targeting vector, ES cells, removal of the PGKneomycin cassette, and the generation of the chimeric mice were as previously published 11 . J1 -/-mice generated from the J1 lox/lox by Cre recombinase expression in the germ cells showed embryonic lethality as described in the conventional knock-out 12 .
J1 lox/lox mice were interbred with Mx-Cre mice 13 to generate J1 lox/loxMx-Cre mice. Inducible activation of the Cre recombinase was done as previously described 11 . The deletion efficiency was assessed by Southern blot analysis of EcoRI digested genomic DNA hybridized with the indicated probe ( Figure 1A ) and quantified using a Phosphorimager (FUJI FILM BAS-1000). 14 using genomic DNA from HSC sorted 8 weeks after transplantation.
BM chimeras
5-FU treatment
N1
lox/lox J1 lox/loxMx-Cre mice were injected with 5-Fluorouracil (Sigma-Aldrich, Buchs, Switzerland) as previously described 15 4 weeks after induced deletion of the floxed genes. The survival rates of the groups were determined.
Immunoblot analysis
Immunoblot analysis was performed as described 16 Sigma-Aldrich).
Flow Cytometry
Single cell suspensions of BM were prepared and stained following standard protocols for FACS analysis using monoclonal antibodies conjugates as previously published 16 .
The anti CD135 antibody (clone A2F10) was from eBioscience and was conjugated to Alexa647 as described 16 .
Results and Discussion
Mx-Cre-induced inactivation of J1 in BM and BM stroma
Figure 1
To circumvent the early embryonic lethality of conventional gene targeted mice for J1 12 , we generated mice in which the first two coding exons are flanked by loxP sites (Fig1A).
The Mx-Cre transgene 13 was intercrossed into J1 lox/lox mice in order to inducibly inactivate the J1 gene in bone marrow (BM) progenitors. The deletion efficiency for the floxed J1 gene segment in BM is close to 100% as shown by Southern blot analysis 11 For personal use only. on August 30, 2017. by guest www.bloodjournal.org From (Fig.1B) . Western blot analysis of primary BM stromal cultures from induced J1 deficient mice demonstrate a complete absence of J1 protein (Fig.1C) , implying that the Mx-Cre system is also suitable for gene inactivation in BM stromal cells. Since J1 is expressed by osteoblasts, which are believed to be part of the HSC stem cell niche 10, 17 , we investigated whether loss of J1 may influence osteoblast outgrowth or number in primary stromal cultures. No difference between J1 deficient and control BM stromal cultures was observed for expression of osteocalcin (an osteoblast specific marker 18 ) examined by Western blot analysis ( In addition, absolute numbers of the total BM compartment or HSCs showed no significant differences (Fig.1E) . These results indicate that J1 and/or N1 are dispensable for HSC steady state homeostasis. However this approach does not address whether either of these proteins is important for HSC selfrenewal under challenge conditions or in a competitive repopulation system. In order to answer these questions, we first used an in vivo challenge system by exposing control
and induced N1J1 double knockout mice to repeated doses of the antimetabolite 5-fluorouracil (5-FU) (Fig.1F) . The percentage of surviving N1J1 mice was at least as high as for control animals indicating that HSCs of the N1J1 deficient animals could reenter the cell cycle in order to repopulate all hematopoietic lineages.
Figure 2
The readout of the 5-FU experiment is survival of the challenged animals. However, it does not address the reconstitution efficiency of J1 and/or N1 deficient HSCs.
Furthermore it is unclear whether wt or N1 deficient HSCs can reconstitute mice in which
For personal use only. on August 30, 2017. by guest www.bloodjournal.org From J1 is inactivated in the BM stroma. Thus competitive mixed bone chimeras were set up in various combinations to address these questions (Fig.2) (Fig.2C) confirming that efficient repopulation can be achieved by N1 deficient HSCs even in absence of J1 expression by the BM stroma.
In conclusion, our results unequivocally demonstrate that J1 mediated N1 signaling is dispensable for HSC self-renewal and differentiation. Nevertheless, we cannot exclude the possibility that other Notch receptors and/or ligands may substitute for N1 and/or J1 in the conditional knockout mice we have employed. Moreover, even if Notch signaling is dispensable for hematopoiesis under physiological conditions, its potential to expand HSCs in vitro could still be exploited to achieve specific therapeutic goals. For personal use only. on August 30, 2017. by guest www.bloodjournal.org From
